drugset
drugset / Trial / NCT05788484

A Study of CDX-585 in Patients With Advanced Malignancies

NCT05788484 ↗

Phase 1 Completed 20 enrolled Celldex Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.

Timeline

Start
2023-05-11
Primary completion
2025-05-21
Completion
2025-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject CDX-585 Unknown — Other

Indications

cholangiocarcinoma colorectal cancer esophageal cancer fallopian tube cancer gastric cancer head and neck cancer malignant pancreatic neoplasm non-small cell lung carcinoma ovarian cancer primary peritoneal carcinoma renal cell carcinoma urothelial carcinoma